HER2-positive breast cancer: Analysis of key market drugs.
By Aine Slowey, Lead Analyst
1 July 2014
I am the Lead Analyst for cardiovascular and metabolic diseases at Datamonitor Healthcare. I have a DPhil in Organic Che...
Read full bio
The failure of Tykerb’s Phase III ALTTO trial in the adjuvant setting will further reinforce Roche’s dominance in the HER2-positive breast cancer market. Sales of Herceptin and new products Kadcyla and Perjeta generate significant commercial reward for Roche, but the upcoming expiry of Herceptin’s patent and the threat of trastuzumab biosimilars could see Roche lose some of its share of this lucrative market.
We have provided an in-depth analysis of key marketed drugs, providing you with new clinical data and comparative evaluations to allow you to discover how this market will shape itself and how this could affect you.
How will our HER2-PositiveBreast Cancer: Marketed Drugs Report benefit you?
- Gain competitive insight
Analysis of clinical and commercial attributes of four key marketed drugs, Herceptin, Kadcyla, Perjeta and Tykerb, and predictions of how each will progress within the market, allowing you to benchmark your drug against those with the highest commercial standing.
- Define your pricing strategy
Explore the implications of the increasing costs of targeted therapies and the potential barriers to uptake of these drugs, helping you to pinpoint potential reimbursement issues in cost-conservative markets enabling you to define your pricing strategy in the HER2-positive breast cancer market.
- Recognise patient needs
Identify the benefits of Roche’s subcutaneous formulation of Herceptin over the intravenous version of the treatment and explore how this will affect the drug’s commercial potential and market standing, enabling you to learn what treatments are preferable to patients while still remaining commercially attractive.
Key Questions answered:
- How will Tykerb’s clinical trial failure affect its market positioning and future commercial potential?
- How will healthcare providers react to the expected cost of the Kadcyla and Perjeta combination therapy and how will this affect its initial uptake?
- What pre-emptive measures have Roche taken to combat Herceptin’s patent expiry in 2014 with biosimilar versions already in phase III development?
|Drug List:||Companies Mentioned:|
Posted in Oncology.